The introduction of treatments designed to change the natural disease course of multiple sclerosis (MS) has focused attention on the economic burden of this disease. Economic evaluations, which analyze the burden of MS on society and the cost effectiveness of new therapies, stress that the economic burden of a disease should be seen in a global perspective and that new treatments offer an opportunity to reduce the burden of the disease in the long term. Effective disease management increasingly involves both specialty and managed care pharmacists to navigate complicated treatment regimens and promote medication adherence. Pharmacists are challenged to choose optimal treatments to decrease future disability in a population in which the disease is highly variable, unpredictable, and very patient specific. The explosion in scientific knowledge over the last decade is overwhelming to both researchers and healthcare practitioners, particularly those who manage patients with MS. In order to be effective in their role, specialty and managed care pharmacists need a sense of the basic pharmaceutical sciences, clinical pharmacy, pharmacy management systems, health policy and ethics, new drug introductions, pharmacoeconomics, and pharmacoepidemiology. This archived webcast will provide managed care and specialty pharmacists with timely information and practical strategies to improve MS patient outcomes in the managed care setting.
To provide managed care and specialty pharmacists with up-to-date information regarding their role in managing patients with MS.
This activity is designed for managed care, specialty, Veterans Affairs, and Department of Defense pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- DESCRIBE the outcomes of clinical trials using disease-modifying therapies (DMTs) for clinically isolated syndrome to explain why initiating treatment early in the course of the disease may decrease disability progression and potentially increase neuroprotection.
- DISCUSS how current treatments can be utilized to optimize patient care and decrease disease progression.
- EVALUATE advanced neuroimaging methodologies when discussing the challenges of assessing patients for treatment success and failure.
- IDENTIFY 2 interventions to increase patient adherence and optimize the utilization of multiple sclerosis therapies.
- COMPARE and CONTRASTthe efficacy of novel approved and emerging therapies to currently available DMTs for reducing disability and relapse rate.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based educational activity will provide a statement for 1.5 contact hour credit (0.15 CEUs) and will be available for download following successful completion of the activity. Successful completion includes taking the pre-test, participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination two more times. ACPE Program #0064-0000-11-208-H01-P. Beginning in 2012, your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website (www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: firstname.lastname@example.org or telephone 847-391-4406.
The estimated time to complete this activity: 1.5 hours.
Release date: January 31, 2012. Expiration date: January 31, 2013.
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The faculty reported the following:
Jacci Bainbridge, PharmD (Chair)
Department of Clinical Pharmacy
University of Colorado at Denver
Health Sciences Center
Jacci Bainbridge, PharmD, reports serving as a consultant for Teva Neurosciences; serving on the speakers' bureau for UCB Pharma; and receiving grants/research support from the National Institutes of Health.
Ronald DeBellis, PharmD, FCCP
Professor and Chair, Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Ronald DeBellis, PharmD, FCCP, reports serving as a consultant for Teva.
Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
Jeffrey D. Dunn, PharmD, MBA, reports serving as a consultant for Biogen IDEC and Teva.
Ellen Whipple Guthrie, PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Multiple Sclerosis Foundation
Fort Lauderdale, Florida
Ellen Whipple Guthrie, PharmD, reports holding stock in Teva Pharmaceuticals.
Marty Mattei, PharmD
Associate Vice President
Pharmacy Products and Services
The TriZetto Group
Greenwood Village, Colorado
Marty Mattei, PharmD, reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Augusto Miravalle, MD
University of Colorado Anschutz Medical Campus
Augusto Miravalle, MD, reports serving as a consultant for ASiM, Bayer Pharmaceuticals, EMD Serono, and Projects in Knowledge; and receiving grants/research support from Biogen IDEC, Teva Pharmaceuticals, and Xenoport.
Sheldon J. Rich, RPh, PhD
President – SJR Associates, LLC
Palm Beach Gardens, Florida
Adjunct Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Sheldon J. Rich, RPh, PhD, reports serving as a consultant for Acorda Therapeutics and Teva Neuroscience.
Melody Ryan, PharmD, MPH, BCPS, CGP
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Department of Neurology
University of Kentucky College of Medicine
Melody Ryan, PharmD, MPH, BCPS, CGP, reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at email@example.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.
Initial Treatment and MRI Basics
Multiple Sclerosis and the Disease-Modifying Therapies
Socioeconomic Considerations with MS Therapies: 2011 Update
Question and Answer Session
What you are about to see is a previously recorded live webcast. Please note that only "home study" credit will be awarded for participating in this archived presentation. No "live" credits are available.
Supported by an educational grant from Teva Neuroscience.
|University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.